You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Genome-wide association studies offer a look at the rare and common contributors to the heart condition, pointing to possible prediction and treatment tools.
The national lockdown reduced the genetic diversity of the SARS-CoV-2 lineages in the UK, the researchers additionally reported.
In Science this week: mapping the embryonic mouse heart, and more.
Bryan Sykes, an Oxford University professor who studied genetic ancestry, has died at 73, the New York Times reports.
The UK's Medicines and Healthcare products Regulatory Authority has approved the SARS-CoV-2 vaccine from Oxford University and AstraZeneca, the Guardian reports.
BuzzFeed News reports that published results from AstraZeneca and Oxford University about their vaccine don't clear up all questions.
Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.
A team led by researchers at University College London studied mutations in almost 47,000 viral genomes collected from patients worldwide.
Late-stage testing indicates the AstraZeneca and Oxford University SARS-CoV-2 vaccine can have up to 90 percent efficacy, the Associated Press reports.
The Guardian reports that AstraZeneca and Oxford University's coronavirus vaccine will likely not be ready for distribution by late December.
According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.
Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.
In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.
Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.